The hepatokine FGF-21 has been shown to be therapeutically beneficial for the treatment of metabolic diseases via reducing fat mass, hyperglycemia, insulin resistance, dyslipidemia, and non-alcoholic steatohepatitis in rodents and non-human primates [63]. This evidence concerns the gene FGF21 and metabolic syndrome.